Leading The Charge
With Diversity Action Plans
Smiling photo of Joseph Coney, M.D., Retina Associates of Cleveland, Lead Investigator, Elevatum Study

Starting in 2025, the FDA will require those seeking approval for pivotal clinical studies to submit a plan for ensuring diversity among trial participants. These Diversity Action Plans (DAPs) ensure the enrollment of patients from underrepresented racial and ethnic populations in clinical studies. Genentech is proud to have successfully submitted 20 DAPs in 2023 - two years ahead of the FDA mandate.

By leading the charge ahead of the deadline, we can integrate and share important learnings with other industry leaders to ensure significantly increased access to equitable care for all patients.

As a Black ophthalmologist, it’s deeply meaningful for me to participate in a study that’s focused on communities of color in a way that no other study has in ophthalmology. And my hope is it opens the door for others to follow suit.
Our people data
As part of our commitment to Diversity & Inclusion, we are sharing enterprise-wide data related to our gender representation, race/ethnicity representation, and pay practices.
Answer The Call
We are looking for transformative visionaries like you to improve lives, patient care, and health equity. Your career is at Genentech.
Join Us
Genentech Logo
Genentech Logo
© 2023 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.